Carfilzomib

Carfilzomib
Clinical data
Trade names	Kyprolis
Other names	PX-171-007
AHFS/Drugs.com	Monograph
MedlinePlus	a612031
License data	EU EMA: by INN; US DailyMed: Carfilzomib; US FDA: Carfilzomib;
Pregnancy; category	AU: C;
Routes of; administration	Intravenous
ATC code	L01XG02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only; EU: Rx-only;
Pharmacokinetic data
Protein binding	97%
Metabolism	Extensive; CYP plays a minor role
Identifiers
	IUPAC name (2S)-4-Methyl-N-[(2S)-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]-4-phenylbutanoyl]amino]pentanamide;
CAS Number	868540-17-4;
PubChem CID	11556711;
IUPHAR/BPS	7420;
DrugBank	DB08889;
ChemSpider	9731489;
UNII	72X6E3J5AR;
KEGG	D08880;
ChEBI	CHEBI:65347;
ChEMBL	ChEMBL451887;
CompTox Dashboard (EPA)	DTXSID4048690 ;
ECHA InfoCard	100.219.957
Chemical and physical data
Formula	C40H57N5O7
Molar mass	719.924 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)[C@@]1(OC1)C)CC(C)C)Cc2ccccc2)CC(C)C)CCc3ccccc3)CN4CCOCC4;
	InChI InChI=1S/C40H57N5O7/c1-27(2)22-32(36(47)40(5)26-52-40)42-39(50)34(24-30-14-10-7-11-15-30)44-38(49)33(23-28(3)4)43-37(48)31(17-16-29-12-8-6-9-13-29)41-35(46)25-45-18-20-51-21-19-45/h6-15,27-28,31-34H,16-26H2,1-5H3,(H,41,46)(H,42,50)(H,43,48)(H,44,49)/t31-,32-,33-,34-,40+/m0/s1; Key:BLMPQMFVWMYDKT-NZTKNTHTSA-N;

Carfilzomib, sold under the brand name Kyprolis, is an anti-cancer medication acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin. It was developed by Onyx Pharmaceuticals.

The US Food and Drug Administration (FDA) approved it in July 2012.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.